An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal coronavirus disease 2019 (COVID-19) vaccine in mice.

Their analyses reveal that a single dose of the vaccine is capable of inducing both neutralizing and binding antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants for a prolonged time period.

Study: An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Image Credit: Vicente Sargues / Shutterstock
Study: An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Image Credit: Vicente Sargues / Shutterstock

A detailed description of the vaccine is currently available on the bioRxiv* preprint server.

Background

As of May 11, 2021, there have been 159 million confirmed cases of COVID-19, including 3.3 million deaths. With the aim of controlling viral transmission, many potential vaccines have been developed and rolled out at record speed. The majority of currently available COVID-19 vaccines contain SARS-CoV-2 spike protein as an immunogen and are based on plasmid DNA, mRNA, viral vector, inactivated virus, or protein subunit. These vaccines are primarily administered via intramuscular injection.

Although most of the COVID-19 vaccines have shown good efficacy and safety levels in both clinical trials and real-world pandemic situations, their effectiveness in diminishing upper respiratory tract infection and preventing person-to-person viral transmission remains largely uncertain. In this context, clinical studies have shown that despite inducing strong systemic antibody responses, intramuscularly administered vaccines are less effective in inducing IgA and IgG-specific anti-spike antibodies in the respiratory mucosa.

In the current study, the scientists have investigated the dose-response, durability, and cross-protective efficacy of an intranasally administered adenovirus-based COVID-19 vaccine (ChAd-SARS-CoV-2-S) containing a prefusion-stabilized spike protein as a vaccine antigen.

Previous studies on human angiotensin-converting enzyme 2 (ACE2)-expressing transgenic mice, hamsters, and non-human primates have shown that this vaccine is capable of inducing strong antibody-mediated, cell-mediated, and mucosal immune responses. The vaccine is currently under investigation in human clinal trials.

Study design

For the study purpose, mice were administered with different doses of the vaccine via the intramuscular or intranasal route. Afterward, the mice were intranasally infected with SARS-CoV-2 or its variants. For various virological assays, the serum and tissue samples were collected from vaccinated mice.

To evaluate the vaccine efficacy vaccinated sera were analyzed for anti-spike binding and neutralizing antibodies. In addition, bone marrow samples collected from vaccinated mice were analyzed for spike-specific IgG- and IgA-secreting plasma cells.  

Important observations

Antibody response

The measurement of serum anti-spike and anti-receptor binding domain (RBD) antibody titers by ELISA revealed that a single dose of intranasally injected vaccine induces significantly higher IgG-specific binding antibodies than intramuscularly injected vaccine after 100 and 200 days of vaccination. In contrast to intramuscularly immunized mice that did not exhibit IgA-specific immunity, significantly higher titers of IgA-specific binding antibodies were observed in mice immunized intranasally. These findings indicate that an intranasal route of vaccine administration is superior to the intramuscular route in inducing strong and long-lasting IgG- and IgA-specific anti-SARS-CoV-2 antibody responses in serum.

Alike binding antibodies, at both 100-day and 200-day post-vaccination time points, significantly higher titers of SARS-CoV-2 neutralizing antibodies were detected in mice immunized intranasally compared to that in intramuscularly-immunized mice.

Regarding antibody responses against different spike and RBD mutations observed in SARS-CoV-2 variants (B.1.1.7, B.1.351, and B.1.1.28 lineages), the findings revealed that the vaccine administered via intranasal route is capable of inducing higher antibody responses against all tested variants of spike and RBD compared to the intramuscularly injected vaccine. Moreover, a greater and more functional antibody response was observed in intranasal vaccination than intramuscular vaccination.   

Long-lived plasma cells

Long-lived plasma cells residing in the bone marrow are considered to be the main players in maintaining antigen-specific antibody levels in serum. The measurement of bone marrow-derived long-lived plasma cells at 200-day post-vaccination revealed 4-fold higher levels of spike-specific IgG- and IgA-secreting long-lived plasma cells in intranasally immunized mice than intramuscularly immunized mice.

Vaccine efficacy against SARS-CoV-2 infection

To evaluate in vivo vaccine efficacy, immunized mice were infected with SARS-CoV-2 after 100 and 200 days of vaccination (intranasal or intramuscular route). The analysis revealed a significantly higher level of protection against SARS-CoV-2 at both time points in intranasal vaccination than intramuscular vaccination. Compared to intranasal vaccination, intramuscular vaccination caused 1000-fold to 30,000-fold higher levels of viral RNA in the lungs.    

Durability of vaccine-induced immunity

The serum samples collected from mice after 6 weeks and 9 months of intranasal vaccination showed high levels of binding and neutralizing antibodies against wildtype SARS-CoV-2. However, a 3-fold to 8-fold reduction in neutralizing ability was observed against SARS-CoV-2 variants.  

Importantly, in mice infected with wildtype virus or SARS-CoV-2 variants after 9 months of intranasal vaccination, significantly lower levels of viral RNA were observed in the upper and lower respiratory tracts, heart, and brain.

Taken together, the study findings reveal that intranasal administration of ChAd-SARS-CoV-2-S vaccine can induce a strong and long-lasting antibody response against wildtype SARS-CoV-2 and its variants in a dose-dependent manner. The study also highlights the advantages of intranasal vaccination over intramuscular vaccination.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha. (2021, May 11). An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo. News-Medical. Retrieved on July 27, 2021 from https://www.news-medical.net/news/20210511/An-intranasal-COVID-19-vaccine-elicits-long-lasting-immunity-against-SARS-CoV-2-variants-in-vivo.aspx.

  • MLA

    Dutta, Sanchari Sinha. "An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo". News-Medical. 27 July 2021. <https://www.news-medical.net/news/20210511/An-intranasal-COVID-19-vaccine-elicits-long-lasting-immunity-against-SARS-CoV-2-variants-in-vivo.aspx>.

  • Chicago

    Dutta, Sanchari Sinha. "An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo". News-Medical. https://www.news-medical.net/news/20210511/An-intranasal-COVID-19-vaccine-elicits-long-lasting-immunity-against-SARS-CoV-2-variants-in-vivo.aspx. (accessed July 27, 2021).

  • Harvard

    Dutta, Sanchari Sinha. 2021. An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo. News-Medical, viewed 27 July 2021, https://www.news-medical.net/news/20210511/An-intranasal-COVID-19-vaccine-elicits-long-lasting-immunity-against-SARS-CoV-2-variants-in-vivo.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
An oral pill for COVID-19? Molnupiravir shows promise